A Study to Provide Brincidofovir to Treat Serious Adenovirus Infection or Disease


Full Title

An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease


Adenoviruses, such as those that cause the common cold, are generally harmless in healthy people. However, adenovirus infections can cause serious problems in people with weakened immune systems, such as those recovering from a bone marrow transplant.

People with serious adenovirus infections may be treated with a drug called cidofovir. However, this medication can cause kidney damage. In this study, patients with serious adenovirus infections are being offered brincidofovir, a modified form of cidofovir which may cause fewer side effects than cidofovir. Brincidofovir is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have serious adenovirus infection or disease.
  • Patients may not have previously received brincidofovir.
  • This study is for patients age 2 months and older.

For more information about this study and to inquire about eligibility, please contact Dr. Genovefa Papanicolaou at 212-639-8361.